Table 1.
The description of the study samples.
| Variables | Values | P value | |
|---|---|---|---|
| Training (n = 223) | Testing (n = 56) | ||
| Teicoplanin trough concentration (mg/L) | 13.32 (8.87,19.12) | 11.291 (7.62,22.11) | 0.603 a |
| Teicoplanin administration | |||
| Loading dose (mg/kg) | 7.91 (6.67, 12.18) | 7.45 (6.09, 12.23) | 0.149 a |
| Times of loading dose | 0.747 d | ||
| <3 | 68 (30.49) | 14 (25) | |
| 3-5 | 149 (66.82) | 41 (73.21) | |
| > 5 | 6 (2.69) | 1 (1.79) | |
| Loading intervals (h) | 0.924 d | ||
| 12 | 201 (90.13) | 52 (92.86) | |
| 24 | 14 (6.28) | 3 (5.36) | |
| Others | 8 (3.59) | 1 (1.79) | |
| Maintenance dose (mg/kg) | 8 (6.09, 12.18) | 7.08 (5.64, 12.23) | 0.086 a |
| Maintenance intervals (h) | 0.249 d | ||
| 12 | 13 (5.83) | 2 (3.57) | |
| 24 | 196 (87.89) | 47 (83.93) | |
| Others | 14 (6.28) | 7 (12.5) | |
| Total duration of treatment (day) | 5 (3, 8) | 4 (3, 6.75) | 0.079 a |
| Demographic information | |||
| Age (years) | 53 (40, 66) | 52.5 (38.25, 65.75) | 0.823 a |
| Height (cm) | 165 (155.07, 168.27) | 165 (155.07, 170) | 0.782 a |
| Weight (kg) | 59 (53.44, 65.7) | 65 (53.44, 73.75) | 0.059 a |
| Gender, male (n, %) | 80 (35.87%) | 25 (44.64%) | 0.226 c |
| APACHE II | 24(20, 28) | 23(19, 26) | 0.053a |
| Laboratory parameters | |||
| ALB (g/L) | 32.32 ± 4.91 | 32.40 ± 4.59 | 0.911 b |
| eGFR (ml/min/L) | 97.06 (61.84, 120.57) | 86.63 (50.61, 111.41) | 0.063 a |
| Cys-C (mg/L) | 1.52 (0.97, 1.7) | 1.6 (1.05, 1.76) | 0.453 a |
| CLcr e (mL/min/1.73m2) | 85.55 (55.43, 125.25) | 78.23 (40.22, 123.97) | 0.317 a |
| AST (IU/L) | 41.7 (22.5, 79.9) | 34.2 (19.63, 81.6) | 0.754 a |
| ALT (IU/L) | 26.5 (14, 49.2) | 24.8 (10.78, 69.25) | 0.695 a |
| TBIL (umol/L) | 20.4 (12.4, 48.1) | 19.25 (13.93, 50.05) | 0.984 a |
| NEU% | 77.1 (64.5,87.5) | 79.5 (67.53,89.1) | 0.457 a |
| PLT (109/L) | 83 (37, 196) | 135.5 (40, 252.25) | 0.142 a |
| Concomitant therapy | |||
| ECMO (n, %) | 11 (4.93%) | 2 (3.57%) | 1.000 d |
| CRRT (n, %) | 61 (27.35%) | 16 (28.57%) | 0.855 c |
| Co-medication f (n, %) | 17 (7.62%) | 3 (5.36%) | 0.774 d |
| Concomitant diseases | |||
| AML (n, %) | 30 (13.45%) | 8 (14.29%) | 0.871 c |
| Hypoproteinemia (n, %) | 143 (64.13%) | 34 (60.71%) | 0.636 c |
| Sepsis, (n, %) | 80 (35.87%) | 14 (25%) | 0.110 c |
APACHE II, acute physiology and chronic health evaluation II; ALB, albumin; Cys-C, cystatin C; eGFR, estimated glomerular clearance; CLcr, creatinine clearance rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; NEU%, the percentage of neutrophils; PLT, platelet count; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy, AML, acute myeloid leukemia.
Measurement data were presented as median and interquartile range (IQR) for non-normal distribution variables and mean ± SD for normal distribution variables. Categorical data were expressed as n (%).
Mann–Whitney U test.
Independent t-test.
Chi-squared test.
Fisher's exact test.
Creatinine clearance was calculated by the Cockcroft formula. CLcr = (140 – age [years]) × weight (WT, kg) × 0.85 (if female)/0.818 × SCr (μmol/L).
Comedication included Furosemide, Amikacin Sulfate, Cyclosporine, Isepamicin Sulfate, Amphotericin B liposome and Colistin Sulfate.